Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
The FDA approved the first generic versions of Mylan’s EpiPen and EpiPen Jr, as shortages of the autoinjectors continue.
Terumo BCT announced that David Perez will retire as president and CEO following nearly 20 years at the company.
Insmed aims to bring a first-in-market therapy to patients in the U.S. suffering from NTM lung disease caused by MAC, a chronic and debilitating condition.
Merck & Co. and Geisinger are in talks with health IT firms that could help take their two new EHR apps to market.
Novocure has teamed up with a cancer physician network to accelerate patient recruitment in its pivotal pancreatic cancer trial.
Mayo Clinic and OmniTier have shown that de novo whole genome sequencing can be done without the need for “supercomputing-level resources."
BioSig received FDA clearance for its first product, the PURE EP system, for analyzing electric heart rhythm signals.
A trio of aging-focused biotechs and research firms formed a joint venture to develop small molecules for a novel target hoping to extend life spans.
Profusa raised more than $45 million in a series C round for its tissue-integrated biosensors.
FundamentalVR launched a virtual surgery platform that uses physical feedback to create a tactile, flight simulator-like experience for surgeons.
Medtronic’s new patient engagement program aims to use game-design elements to encourage diabetes patients to better track their blood glucose levels.